Zolunicant
Based on 1 Customer Validation
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis.
For research use only. We do not sell to patients.
- Purity : 99.59%
- CAS No.: 188125-42-0
- Formula: C22H28N2O3
- Molecular Weight:368.47
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Parasite Isoforms
More
Biological Activity
Description
IC50 & Target
|
Leishmania |
In Vitro
Zolunicant (18-MC; 0.01-100 μM) shows an inhibitory activity against nicotinic α3β4 receptors with an IC50 of 0.90 μM[1].
. Zolunicant (18-MCOR; 0-20 μg/ml; 24h) also shows antiamastigote activity against L. amazonensis-infected macrophage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:L. amazonensis-infected macrophage
-
Concentration:0, 1, 10,15 and 20 μg/ml
-
Incubation Time:24 h
-
Result:Decreased the amastigote survival by 73, 84, and 92%, respectively in the treatment with 18-MCOR at 1, 10, or 20 μg/ml.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Naïve female Long-Evans derived rats[3]
-
Dosage:0,10 and 20 μg
-
Administration:Intravenous administration; once a day; 14 days
-
Result:Infused into the medial habenula and interpeduncular nucleus decreased morphine self-administration (interpeduncular nucleus: F(5,29) = 6.89, P < 0.0001; medial habenula: F(4,28) = 3.07, P < 0.03).
Chemical Information
-
CAS No. 188125-42-0
-
Appearance Solid
-
Molecular Weight 368.47
-
Formula C22H28N2O3
-
Color White to off-white
-
SMILES
COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C54)C[C@@](C[C@@H]3CCOC)([H])C1)=O
-
Synonyms
MM-110; (±)-18-Methoxycoronaridine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492(2-3):159-67. [Content Brief]
[2]. Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(7):2111-5. [Content Brief]
[3]. Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537(1-3):94-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)